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Abstract
Background: Biliary tract cancers have limitations in information about different location-related pathogenesis and
clinico-pathological characteristics. The goal of this study was to investigate anatomical site-related similarities and
differences in biliary tract cancers and to assess the expression and clinical significance of functional proteins such
as p53, cyclin D1, survivin, thymidine phosphorylase, and ERCC1.
Methods: One hundred and sixty-one patients with biliary tract adenocarcinomas, who underwent curative or
palliative surgery in a single institution between October 1994 and December 2003 were evaluated, retrospectively.
The level of protein expression of p53, cyclin D1, survivin, thymidine phosphorylase, and ERCC1 was assessed by
immunohistochemistry.
Results: With respect to clinico-pathological characteristics, gallbladder cancer was more frequent in women, and
bile duct cancer was more common in men. Perineural invasion was more common in bile duct cancer.
Recurrence as a distant metastasis was more common in gallbladder cancer. Immunohistochemical analysis
revealed that thymidine phosphorylase expression was significantly higher in gallbladder cancer than in bile duct
cancer. Positive thymidine phosphorylase and p53 staining were associated with an advanced stage. Differentiation,
vascular invasion, perineural invasion, lymphatic invasion, lymph node metastasis, and TNM stage independently
predicted poor prognosis in biliary tract cancer. These correlations were seen more clearly in gallbladder cancer.
The immunohistochemical staining patterns of p53, cyclin D1, survivin, thymidine phosphorylase, and ERCC1
showed no prognostic significance in biliary tract cancers.
Conclusions: We concluded that gallbladder and bile duct cancers are considered to be separate diseases with
different clinico-pathological characteristics and prognostic factors. In addition, we hypothesize that high
expression of thymidine phosphorylase by gallbladder cancer results in a higher response rate to capecitabine by
gallbladder cancer than bile duct cancer.
Background
Biliary tract cancers are relatively uncommon cancers in
the western countries accounting for approximately 4%
of gastrointestinal malignancies, but they are more com-
mon in Asia [1]. Based on the data of the National Can-
cer Registry in 2007, it is the eighth most common
cancer in Korea, with an annual incidence of 4,419 cases
per 100,000. Although surgical resection remains the
only potentially curative treatment, many patients are
not eligible for surgery because of the advanced stage at
the time of diagnosis. The prognosis for patients with
advanced disease is dismal, and the median survival is
less than 6 months [1]. Characteristics such as general
rarity, difficulty in diagnosis, and overall poor prognosis
lead to a paucity of data from which the natural history
and optimal treatment regimens can be defined.
Additionally, the molecular basis of these tumors and
biomarkers related to prognosis or response to
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cancers can be divided into bile duct cancer and gall-
bladder (GB) cancer. GB and bile duct cancer have been
considered similar, and hence have been treated with
the same treatment protocols or clinical trials. However,
they are currently considered different disease entities,
because they have been shown to be distinct in clinical
behavior and response to anti-cancer treatments.
5-fluorouracil (5-FU) is the most evaluated drug for
GB and bile duct malignancies as a single agent or in
combination. Recently, gemcitabine and cisplatin have
shown improved survival of patients with biliary tract
cancer compared with gemcitabine alone [2]. Thymidine
phosphorylase (TP) is an enzyme that converts
5’-deoxy-5-fluorouridine (5’-DFUR) to 5-FU. The
expression of TP might be correlated with the efficacy
of 5-FU-based chemotherapy [3]. Overexpression of the
excision repair cross-complementation group 1 (ERCC1)
gene, which is crucial in the repair of cisplatin-induced
DNA adducts, has been reported to negatively influence
to effectiveness of cisplatin-based chemotherapy [4].
This study aims to compare the clinico-pathological
characteristics and prognostic factors of GB and bile
duct cancers, and also investigate the expression and
clinical significance of TP and ERCC1, including several
cell-cycle regulatory proteins in biliary tract cancers.
Methods
Patients
One hundred and sixty-one patients who underwent
curative or palliative surgery for extrahepatic cholangio-
carinoma, Klatskin tumor or GB cancer in Kangnam St.
Mary’s Hospital between October 1994 and December
2003 were evaluated. We excluded patients with intrahe-
patic cholangiocarinoma, because this type of cancer has
been known to have different clinico-pathological char-
acteristics from the other two types of bile duct cancers.
Among 161 patients, 65 (40.4%) patients had been diag-
n o s e dw i t hG Bc a n c e r ,a n d9 6( 5 9 . 6 % )p a t i e n t sw i t h
extrahepatic and Klatskin tumor (BDC). Clinical records
and pathological reports were reviewed retrospectively.
The following clinical data were collected: patient age,
gender, objectives of operation, adjuvant therapy, tumor
staging, recurrence, and survival. Ethics committee
approval was obtained from the Institutional Review
Board of The Catholic University of Korea, Seoul St.
Mary’s Hospital, Seoul, Korea. Informed consent was
provided according to the Declaration of Helsinki.
Tissue microarray and Immunohistochemical staining
To construct the tissue microarray block, small core
biopsies (3.0 mm diameter) were taken from non-necro-
tic, morphologically representative areas of paraffin-
embedded tumor tissues. One hundred and sixty-one
tissue cores from each specimen were assembled on a
recipient paraffin block with a precision instrument
(Micro Digital Co. Korea). After construction, 5 μm sec-
tions were cut and hematoxylin-eosin staining was per-
formed on the initial slide for histological verification.
Immunohistochemical staining was performed on the 5
μm sections of the tissue microarray blocks. Paraffin sec-
tions were deparaffinized in xylene and rehydrated in
serial graded ethanol, and then subjected to microwave
antigen retrieval. Endogenous peroxidase activity was
blocked with 0.3% hydrogen peroxide in methanol. Sec-
tions were incubated for 1 hour at room temperature or
at 4 ℃ overnight with the following primary antibodies
at the specified dilutions: TP (Zymed Laboratories, South
San Francisco, CA, USA) diluted 1:100, ERCC1 (Neo-
Markers, Fremont, CA, USA) diluted 1:200, survivin
(NeoMarkers, Fremont, CA, USA) diluted 1:50, p53
(DAKO Corporation, Carpinteria, CA, USA) diluted
1:100, and cyclin D1 (DAKO Corporation, Carpinteria,
C A ,U S A )d i l u t e d1 : 5 0 .I m m u n o histochemical staining
was performed using the rabbit or mouse DAKO Chem-
Mate TM EnVision TM system and the Peroxidase/DAB
kit (DAKO). Sections were then counterstained with
Mayer hematoxylin and dehydrated, cleared and
mounted. The results were interpreted by two indepen-
dent pathologists who were blinded to the specific diag-
nosis and prognosis for each case. The staining intensity
was scored on a three-tiered scale: score 0 = less than
10% of cells positive; 1 = 10-49% positive; and 2 = more
than 50% of cells positive. The criterion for positive stain-
ing was more than 1 + of tumor cells that showed dis-
tinct nuclear or cytoplasmic staining (Figure 1) [5-8].
Statistical analysis
Overall survival (OS) was defined as the time from the
date of diagnosis to the date of death or last follow-up.
Time to recurrence (TTR) was defined as the time from
the date of diagnosis to the date of recurrence. Continu-
ous and categorical variables were compared using the
Student’s t-test and the chi-square test. Univariate survi-
val analysis and survival curves were estimated using the
Kaplan-Meier method, and the log-rank test was applied
to assess statistical differences. Multivariate analysis was
performed with the Cox hazards regression model. All
statistical analyses were performed using the SPSS pro-
gram (version 15.0) and p < 0.05 was considered statisti-
cally significant.
Results
Patient characteristics
The clinico-pathological characteristics of the 161
patients included in our study are summarized in Table
1. The median age of the patients was 62 (range 35-87)
years. GB cancer was more frequent in women, and
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no significant difference in age, stage and resectability
between GB cancer and BDC. Among 161 patients, 127
patients experienced surgical resection with curative
intent, and 70 patients (55.1%) took adjuvant therapy
with chemotherapy or chemo-radiation based on 5-FU.
Immunohistochemical staining and correlation with
clinico-pathological variables
Histopathology showed that there was no significant dif-
ference in differentiation, vascular invasion, and lympha-
tic invasion between GB cancer and BDC. However,
BDC showed significantly higher perineural invasion
compared to GB cancer (p = 0.001) (Table 1). The
immunohistochemical staining results are listed in Table
2. Immunohistochemistry results of some tissue cores
cannot be determined, because of inadequate or incor-
rect expression and loss of tissue samples in the tissue
microarray. Among all cases on which interpretation of
immunohistochemistry was possible, 72 cases (56.7%)
and 35 cases (26.7%) showed positive expression for p53
and cyclin D1, respectively, 54 cases (41.9%) for survivin,
and 78 cases (65.0%) for TP. However, ERCC1 expres-
sion was mostly negative in 74 cases (65.5%). In com-
parison, TP expression was significantly higher in GB
cancer than in BDC (p = 0.006). We analyzed the corre-
lations between the clinico-pathololgical findings and
the expression of these proteins (Table 3). For all
Figure 1 Cyclin D1, survivin, ERCC1, and TP expressions by immunohistochemistry in biliary tract cancer (magnification ×200).
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with an advanced stage compared to tumors with nega-
tive staining (p = 0.027 and p = 0.009, respectively).
Other significant correlations with clinico-pathological
variables were not observed.
Clinical outcome: recurrence & survival analysis
Among 127 patients with curative resection, the assess-
ment of recurrence was possible in 117 patients. Seventy
patients (59.8%) developed recurrence at a median of 14
months. Recurrence occurred in 50 patients (65.7%)
with BDC and 20 patients (48.7%) with GB cancer (p =
0.049). The median TTR for patients with GB cancer
and BDC were 14 and 17 months, respectively (p =
0.636) (Figure 2A). The patterns of recurrence were
classified into three types; local, regional, and distant
recurrence. Local recurrence is defined as recurrence of
the cancer at the resection sites. Regional recurrence is
defined as recurrence at the lymph nodes near the pri-
mary site. Distant recurrence is defined as the recur-
rence of the cancer in an organ distant from the
primary site. Local recurrence was more common in
BDC (32.0% vs 5.0%), while recurrence as a distant
metastasis was more common in GB cancer (35.0% vs
18.0%) (p = 0.041). The correlation analysis with protein
expression showed that there was no significant associa-
tion of protein expression with recurrence rate, pattern,
or TTR.
The median OS time of patients with GB cancer and
BDC was 20 and 21 months, respectively. There was no
significant difference in OS (p = 0.728) (Figure 2B). In
univariate analysis, the significant factors affecting OS
were differentiation, vascular invasion, perineural inva-
sion, lymphatic invasion, lymph node metastasis, and
Table 1 Clinico-pathological characteristics of the biliary tract cancer patients
Characteristics All patients (n = 161) GB cancer (n = 65) Bile duct cancer (n = 96) p-value
No. of patients % No. of patients % No. of patients %
Age, years 0.265
Mean ± SD 61.9 ± 9.8 63.4 ± 11.4 60.9 ± 8.5
Sex 0.001
Male 95 59.0 28 43.1 67 69.8
Female 66 41.0 37 56.9 29 30.2
Resectability 0.242
Curative 127 78.9 49 75.4 78 81.3
Palliative 34 21.1 16 24.6 18 18.7
Adjuvant therapy 70 43.4 30 46.1 40 41.6 0.229
Histopathology
Well differentiated 51 31.6 23 35.3 28 29.1 0.243
Vascular invasion 13 8.0 5 7.6 8 8.3 0.606
Perineural invasion 82 50.9 15 23.0 67 69.7 0.001
Lymphatic invasion 53 32.9 24 36.9 29 30.2 0.161
LN metastases 60 37.2 25 38.4 35 36.4 0.381
TNM stage 0.105
I 56 35.0 22 33.8 34 35.8
II 66 41.3 24 36.9 42 44.2
III 14 8.7 4 6.2 10 10.5
IV 24 15.0 15 23.1 9 9.5
GB, gallbladder; SD, standard deviation; LN, lymph node.
Table 2 Immunohistochemical staining for tumors
stratified by anatomical sites
Variable All
patients
GB
cancer
Bile duct
cancer
p-value
No. % No. % No. %
P53 (n = 127)
Positive 72 56.7 32 61.5 40 53.3 0.231
Negative 55 43.3 20 38.5 35 46.7
Cyclin D1 (n = 131)
Positive 35 26.7 18 33.3 17 22.1 0.109
Negative 96 73.3 36 66.7 60 77.9
Survivin (n = 129)
Positive 54 41.9 20 37.7 34 44.7 0.271
Negative 75 58.1 33 62.3 42 55.3
TP (n = 120)
Positive 78 65.0 40 78.4 38 55.1 0.006
Negative 42 35.0 11 21.6 31 44.9
ERCC1 (n = 113)
Positive 39 34.5 18 36.7 21 32.8 0.406
Negative 74 65.5 31 63.3 43 67.2
GB, gallbladder; TP, thymidine phosphorylase; ERCC1, excision repair cross
complementing protein 1.
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by type of cancer, these correlations were observed to
be identical in GB cancer. Meanwhile, only two factors,
differentiation and perineural invasion, were significantly
correlated with survival time in BDC. In multivariate
survival analysis, differentiation and TNM stage showed
a significant impact on OS in GB cancer (HR = 0.472,
1.532; p = 0.039, 0.042). Meanwhile, in BDC, TNM
stage was only significant prognostic factor affecting sur-
vival (HR = 2.312; p = 0.001). The expression of p53,
cyclin D1, survivin, TP, and ERCC1 did not indepen-
dently predict poor outcome in univariate analysis.
Among the 66 patients who received adjuvant treat-
ment, there was no significant difference in TTR and
OS associated with TP and ERCC1 expression (p =
0.212, 0.322 for TP; p = 0.591, 0.794 for ERCC1).
Discussion
Biliary tract cancer is a heterogeneous disease with
diverse anatomical sites. In the present study, we inves-
tigated the entire spectrum of biliary tract cancer to
define anatomical site-related similarities and differ-
ences. Several differences were observed between GB
cancer and BDC. In clinico-pathological characteristics,
Figure 2 Kaplan-Meier survival curves for time to recurrence (A) and overall survival (B) in biliary tract cancer according to
anatomical sites.
Table 3 Immunohistochemical staining for tumors stratified by clinico-pathological variables
Variable TP ERCC1 Cyclin D1 Survivin P53
No. p No. p No. p No. p No. p
Differentiation
Well 18 0.096 11 0.557 9 0.405 14 0.344 17 0.190
Others 57 28 26 39 51
Vascular invasion
Yes 10 0.112 3 0.383 3 0.592 4 0.495 6 0.459
No 61 32 30 46 60
Perineural invasion
Yes 42 0.171 23 0.087 19 0.528 30 0.258 40 0.222
No 28 11 14 19 25
Lymphatic invasion
Yes 30 0.350 17 0.181 14 0.311 16 0.170 28 0.226
No 41 18 19 34 38
LN metastasis
Yes 32 0.310 19 0.126 14 0.470 24 0.091 18 0.274
No 42 19 21 29 31
T stage
17 0.027 2 0.083 3 0.442 10 0.806 8 0.009
2 2 2 1 41 01 21 6
3 3 5 1 51 72 64 1
4 1 48567
TP, thymidine phosphorylase; ERCC1, excision repair cross complementing protein 1.
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more common in men. These sex differences are prob-
ably related to the higher incidence of gallstones in
women and of primary sclerosing cholangitis in men,
which are known risk factors for GB cancer and BDC,
respectively [1]. Another anatomical site-related differ-
ence was the frequency of perineural invasion. Peri-
neural invasion is a distinct pathological entity that can
be observed in the absence of lymphatic and vascular
invasion [9]. Although the pathogenesis and clinical sig-
nificance of perineural invasion remain unclear, it is
considered an under-recognized route of metastatic
spread. For some malignancies including head and neck,
pancreas, colorectum, and prostate, perineural invasion
has been associated with a lower 5 year survival rate
and a more advanced disease stage [9]. In our study,
perineural invasion was observed more frequently in
BDC than in GB cancer. Additionally, univariate analysis
revealed that perineural invasion was one of the prog-
nostic factors in biliary tract cancer. Meanwhile, some
differences were found in recurrence patterns and prog-
nostic factors between GB cancer and BDC. BDC had
higher local recurrence than GB cancer, while recur-
rence as a distant metastasis was more common in GB
cancer. These differences should be considered to deter-
mine adjuvant therapy after curative resection. In uni-
variate analysis, differentiation, vascular invasion,
perineural invasion, lymphatic invasion, lymph node
metastasis, and TNM stage independently predicted
poor prognosis in biliary tract cancer. These correlations
were seen more clearly in GB cancer than in BDC. Also,
in multivariate analysis, differentiation and TNM stage
showed a prognostic impact on survival in biliary tract
cancer. Taken together, GB cancer and BDC are thought
to be separate diseases with differences in pathogenesis
influencing clinical behavior.
We assessed the expression of p53, cyclin D1 and survi-
vin, to compare the differences in molecular changes asso-
ciated with the prognosis between BDC and GB cancer.
Apoptosis and cell cycle control are processes required for
the regulation of cellular homeostasis. Chronic imbalance
between apoptosis and cell proliferation is the first step of
carcinogenesis in all tumors. Therefore, prognostic signifi-
cance of cell cycle regulatory protein such as p53 and
Table 4 Univariate survival analysis according to clinico-pathological variables
Variable All patients GB cancer Bile duct cancer
Median Survival p Median Survival p Median Survival p
Anatomic location GB 22 0.939
Bile duct 24
Well differentiated Yes 99 0.001 . 0.001 85 0.001
No 18 17 19
Vascular invasion Positive 13 0.022 12 0.029 13 0.261
Negative 27 27 26
Perineural invasion Positive 19 0.001 16 0.029 19 0.005
Negative 40 30 .
Lymphatic invasion Positive 18 0.011 16 0.047 18 0.080
Negative 31 30 31
Lymph node metastasis Positive 18 0.001 38 0.001 21 0.058
Negative 32 10 30
Stage 1 83 0.001 . 0.001 36 0.069
22 2 2 0 2 6
31 2 9 1 3
4 558
P53 Positive 20 0.210 19 0.409 24 0.374
Negative 30 30 35
Cyclin D1 Positve 25 0.890 20 0.943 25 0.962
Negative 22 21 32
Survivin Positive 27 0.339 20 0.995 58 0.267
Negative 22 21 25
TP Positive 22 0.463 22 0.625 22 0.194
Negative 21 19 32
ERCC1 Positive 18 0.241 21 0.903 14 0.073
Negative 27 20 33
GB, gallbladder; TP, thymidine phosphorylase; ERCC1, excision repair cross complementing protein 1.
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investigated in malignancies [10-13]. Kim et al. reported
the expression and clinical significance of cell cycle regula-
tory proteins in biliary tract cancer. They presented that
cyclin D1 overexpression was more common in extrahepa-
tic bile duct cancer than in GB cancer. In univariate analy-
sis, cyclin D1 and p53 showed no prognostic impact on
survival in biliary tract cancer [10]. Jarnagin et al. also pre-
sented that biliary tract cancers differentially expressed
cell cycle regulatory protein based on tumor location and
morphology. According to their results, cyclin D1 overex-
pression varied based on anatomic site, and it was less
common in GB cancer. However, there was no difference
in p53 overexpression according to anatomic site, and
prognostic roles were not identified for cyclin D1 and p53
[11]. In our study, there was no difference in p53 and
cyclin D1 overexpression based on anatomic site, and also
they were no prognostic impact on survival in BDC and
GB cancer, respectively. Survivin is a member of the inhi-
bitor of apoptosis family that regulates cell division and
suppresses apoptosis [8]. In previous reports, survivin
overexpression was correlated with poor prognosis in
some gastrointestinal malignancies such as gastric cancer
and pancreatic cancer [8]. Javel et al. also reported that
nuclear survivin expression was associated with poor prog-
nosis in cholangiocarcinoma [14]. However, in our study,
there was no difference in survivin expression according
to anatomic site, and no correlation between survivin
expression and prognosis in biliary tract cancer.
Additionally, we examined the expression of TP and
ERCC1 associated with the response to 5-FU and cispla-
tin chemotherapy [15]. No significant differences were
found in the expression of p53, cyclin D1, survivin, and
ERCC1 between GB cancer and BDC. However, TP
expression was significantly higher in GB cancer than in
BDC. This result can explain why these two cancers have
shown different response rates to capecitabine combina-
tion chemotherapy in many clinical trials. TP represents
the rate-limiting enzyme in the activation of 5’-DFUR
and capecitabine. The 5-FU prodrug capecitabine is
metabolized to 5-FU through a three-step enzymatic con-
version. In the final step, 5’-DFUR is metabolized to the
active form 5-FU by TP. Therefore, the sensitivity of
tumor cells to capecitabine might be enhanced by
increasing TP expression [3,16]. Actually, Kim et al. pre-
sented results from a phase II study of capecitabine plus
cisplatin as a first-line chemotherapy for advanced biliary
cancer. According to their results, GB cancer appeared to
respond better to capecitabine and cisplatin treatment
than BDC (32% vs 13%) [17,18]. In another phase II
study with capecitabine and oxaliplatin, Nehls et al.
reported that the response rates for GB, extrahepatic, and
intrahepatic cholangiocarcinoma were 30%, 25%, and 0%,
respectively [19]. In this study, we cannot access the
clinical correlations between TP expression and response
to capecitabine and survival, because capecitabine for
biliary tract cancers was unavailable in Korea during
1994-2003. However, based on our results, correlative
studies will be warranted. Also, in the future, randomized
trials of biliary tract cancer should be performed based
on stratification by anatomical site. Meanwhile, correla-
tion studies with clinico-pathological variables revealed a
significant association between positive TP and p53 stain-
ing with an advanced stage of the disease. These results
are in accordance with previous studies, and the pro-
angiogenic activity of TP can explain the more aggressive
behavior of TP-expressing tumors [3].
Conclusions
In summary, there were some differences in clinico-
pathological characteristics, prognostic factors, and
recurrence patterns between GB cancer and BDC. There-
fore, these differences should be considered when plan-
ning clinical trials and treatments. Additionally, further
studies may be required to evaluate whether TP expres-
sion can be used as a predictive marker for the clinical
response to capecitabine chemotherapy in GB cancer.
Acknowledgements
We thank Dr. Jung Seok Yu for contribution in editing the figures. No
specific funding was received.
Author details
1Division of Medical Oncology, Department of Internal Medicine, Uijeongbu
St. Mary’s Hospital, Kyonggi-do, Korea.
2Division of Medical Oncology,
Department of Internal Medicine, Seoul St. Mary’s Hospital, Seoul, Korea.
3Department of Hospital Pathology, Seoul St. Mary’s Hospital, Seoul, Korea.
4Department of Surgery, Seoul St. Mary’s Hospital, Seoul, Korea.
5Division of
Gastroenterology, Department of Internal Medicine, Seoul St. Mary’s Hospital,
Seoul, Korea.
Authors’ contributions
HSW drafted the manuscript. HSW, MAL, DGK, YKY, THH and ISL collected
the data and followed the patients. ESC evaluated H&E stained and
immunostained slides. DGK, YKY, and THH provided the clinical specimens
for this study and clinical perspective. MAL designed the study and helped
with the manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 30 April 2010 Accepted: 19 October 2010
Published: 19 October 2010
References
1. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM: Biliary
tract cancers. N Engl J Med 1999, 341(18):1368-1378.
2. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A,
et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract
cancer. N Engl J Med 2010, 362(14):1273-1281.
3. Andreetta C, Puppin C, Minisini A, Valent F, Pegolo E, Damante G, et al:
Thymidine phosphorylase expression and benefit from capecitabine in
patients with advanced breast cancer. Ann Oncol 2009, 20(2):265-271.
4. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, et al:
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based
adjuvant chemotherapy. N Engl J Med 2006, 355(10):983-991.
Won et al. BMC Cancer 2010, 10:564
http://www.biomedcentral.com/1471-2407/10/564
Page 7 of 85. Andino L, Cagle PT, Murer B, Lu L, Popper HH, Galateau-Salle F, Sienko AE,
Barrios R, Zander DS: Pleuropulmonary desmoid tumors:
immunohistochemical comparison with solitary fibrous tumors and
assessment of beta-catenin and cyclin D1 expression. Arch Pathol Lab
Med 2006, 130(10):1503-1509.
6. Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M, Kaibara N: The
expression of thymidine phosphorylase correlates with angiogenesis
and the efficacy of chemotherapy using fluorouracil derivatives in
advanced gastric carcinoma. Br J Cancer 1999, 81(3):484-489.
7. Kim SH, Kwon HC, Oh SY, Lee DM, Lee S, Lee JH, Roh MS, Kim DC, Park KJ,
Choi HJ, Kim HJ: Prognostic value of ERCC1, thymidylate synthase, and
glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in
advanced colorectal cancer. Am J Clin Oncol 2009, 32(1):38-43.
8. Song KY, Jung CK, Park WS, Park CH: Expression of the antiapoptosis gene
Survivin predicts poor prognosis of stage III gastric adenocarcinoma. Jpn
J Clin Oncol 2009, 39(5):290-296.
9. Liebig C, Ayala G, Wilks JA, Berger DH, Albo D: Perineural invasion in
cancer: a review of the literature. Cancer 2009, 115(15):3379-3391.
10. Kim WB, Han HJ, Lee HJ, Park SS, Song TJ, Kim HK, et al: Expression and
clinical significance of cell cycle regulatory proteins in gallbladder and
extrahepatic bile duct cancer. Ann Surg Oncol 2009, 16(1):23-34.
11. Jarnagin WR, Klimstra DS, Hezel M, Gonen M, Fong Y, Roggin K, et al:
Differential cell cycle-regulatory protein expression in biliary tract
adenocarcinoma: correlation with anatomic site, pathologic variables,
and clinical outcome. J Clin Oncol 2006, 24(7):1152-1160.
12. Shen YC, Hu FC, Jeng YM, Chang YT, Lin ZZ, Chang MC, et al: Nuclear
overexpression of mitotic regulatory proteins in biliary tract cancer:
correlation with clinicopathologic features and patient survival. Cancer
Epidemiol Biomarkers Prev 2009, 18(2):417-423.
13. Hui AM, Cui X, Makuuchi M, Li X, Shi YZ, Takayama T: Decreased p27(Kip1)
expression and cyclin D1 overexpression, alone and in combination,
influence recurrence and survival of patients with resectable
extrahepatic bile duct carcinoma. Hepatology 1999, 30(5):1167-1173.
14. Javle MM, Tan D, Yu J, LeVea CM, Li F, Kuvshinoff BW, Gibbs JF: Nuclear
survivin expression predicts poor outcome in cholangiocarcinoma.
Hepatogastroenterology 2004, 51(60):1653-1657.
15. Uchida K, Danenberg PV, Danenberg KD, Grem JL: Thymidylate synthase,
dihydropyrimidine dehydrogenase, ERCC1, and thymidine
phosphorylase gene expression in primary and metastatic
gastrointestinal adenocarcinoma tissue in patients treated on a phase I
trial of oxaliplatin and capecitabine. BMC Cancer 2008, 8:386.
16. Ahn MJ, Choi JH, Oh HS, Lee YY, Kim IS, Choi IY, et al: Thymidylate
Synthase, Thymidine Phosphorylase, VEGF and p53 Protein Expression in
Primary Colorectal Cancer for Predicting Response to 5-fluorouracil-
based Chemotherapy. Cancer Res Treat 2005, 37(4):216-222.
17. Kim TW, Chang HM, Kang HJ, Lee JR, Ryu MH, Ahn JH, et al: Phase II study
of capecitabine plus cisplatin as first-line chemotherapy in advanced
biliary cancer. Ann Oncol 2003, 14(7):1115-1120.
18. Hong YS, Lee J, Lee SC, Hwang IG, Choi SH, Heo JS, et al: Phase II study of
capecitabine and cisplatin in previously untreated advanced biliary tract
cancer. Cancer Chemother Pharmacol 2007, 60(3):321-328.
19. Nehls O, Oettle H, Hartmann JT, Hofheinz RD, Hass HG, Horger MS, et al:
Capecitabine plus oxaliplatin as first-line treatment in patients with
advanced biliary system adenocarcinoma: a prospective multicentre
phase II trial. Br J Cancer 2008, 98(2):309-315.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/10/564/prepub
doi:10.1186/1471-2407-10-564
Cite this article as: Won et al.: Comparison of thymidine phosphorylase
expression and prognostic factors in gallbladder and bile duct cancer.
BMC Cancer 2010 10:564.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Won et al. BMC Cancer 2010, 10:564
http://www.biomedcentral.com/1471-2407/10/564
Page 8 of 8